ARTHI SCANS

Obli Towers, 594, D.B. Road, R. S. Puram, Coimbatore-641 002. Mobile : 99430 99994   email: info@arthiscans.com

Patient Name : MR. GOPALAKRISHNAN R

Age / Gender : 60 years / Male

Patient ID : 70277

Referral : MediWheel

Collection Time : Nov 27, 2021, 08:28 a.m.

Reporting Time : Nov 27, 2021, 03:38 p.m.

Sample ID :

002233121

Test Description	Value(s)	Reference Range	
COMPLETE BLOOD COUNT (CBC)			
ESR	**9**	13.5 - 18.0	mm/hr
Hemoglobin (Hb)	14.0	13.5 - 18.0	gm/dL
Erythrocyte (RBC) Count	4.80	4.7 - 6.0	mil/cu.mm
Packed Cell Volume (PCV)	**41.4**	42 - 52	%
Mean Cell Volume (MCV)	86.25	78 - 100	fL
Mean Cell Haemoglobin (MCH)	29.17	27 - 31	pg
Mean Corpuscular Hb Concn. (MCHC)	33.82	32 - 36	g/dL
Red Cell Distribution Width (RDW)	13.0	11.5 - 14.0	%
Total Leucocytes (WBC) Count	6660	4000-10000	cell/cu.mm
Neutrophils	60	40 - 80	%
Lymphocytes	24	20 - 40	%
Monocytes	8	2 - 10	%
Eosinophils	**8**	1 - 6	%
Basophils	**0**	1-2	%
Absolute Neutrophil Count	3996	2000 - 7000	/c.mm
Absolute Lymphocyte Count	1598.40	1000 - 3000	/c.mm
Absolute Monocyte Count	532.80	200 - 1000	/c.mm
Absolute Eosinophil Count	**532.80**	20 - 500	/c.mm
Absolute Basophils Count	**0**	20 - 100	/c.mm
Platelet Count	277	150 - 450	10^3/ul
Mean Platelet Volume (MPV)	10.2	7.2 - 11.7	fL
PCT	0.28	0.2 - 0.5	%
PDW	11.3	9.0 - 17.0	%

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,

Scan to Validate

ARTHI SCANS

Obli Towers, 594, D.B. Road, R. S. Puram, Coimbatore-641 002. Mobile : 99430 99994   email: info@arthiscans.com

Patient Name : MR. GOPALAKRISHNAN R		**Referral :** MediWheel	
Age / Gender : 60 years / Male		**Collection Time :** Nov 27, 2021, 08:28 a.m.	
Patient ID : 70277		**Reporting Time :** Nov 27, 2021, 03:38 p.m.	

Sample ID :

002233121

Test Description	Value(s)	Reference Range	

URINE COMPLETE ANALYSIS,

Physical Examination

Quantity	22	-	ml
Colour	Pale Yellow	Pale yellow/Yellow	
Appearance	Clear	Clear	
Specific Gravity	1.020	1.005-1.025	
pH	6.0	5.0 - 8.0	
Deposit	**Present**	Absent	

Chemical Examination

Protein	Absent	Absent
Sugar	Absent	Absent
Ketones	Absent	Absent
Bile Salt	Absent	Absent
Bile Pigment	Absent	Absent
Urobilinogen	Normal	Normal

Microscopic Examination (/hpf)

Pus Cell	2-4	Upto 5
Epithelial Cells	1-2	Upto 5
Red Blood Cells	Absent	Absent
Casts	Absent	Absent
Crystals	Absent	Absent
Amorphous Deposit	Absent	Absent
Yeast Cells	Absent	Absent
Bacteria	Absent	Absent
Other findings	Not seen	Not seen

DR.UMA SAROJINI .K MBBS.,DCP.,

Scan to Validate

ARTHI SCANS

Patient Name : MR. GOPALAKRISHNAN R

Age / Gender : 60 years / Male

Patient ID : 70277

Referral : MediWheel

Collection Time : Nov 27, 2021, 08:28 a.m.

Reporting Time : Nov 27, 2021, 03:38 p.m.

Sample ID :

002233121

Test Description	Value(s)	Reference Range

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,

Scan to Validate

ARTHI SCANS

Obli Towers, 594, D.B. Road, R. S. Puram, Coimbatore-641 002. Mobile : 99430 99994   email: info@arthiscans.com

Patient Name : MR. GOPALAKRISHNAN R

Age / Gender : 60 years / Male

Patient ID : 70277

Referral : MediWheel

Collection Time : Nov 27, 2021, 08:28 a.m.

Reporting Time : Nov 27, 2021, 03:38 p.m.

Sample ID :

002233121

Test Description	Value(s)	Reference Range	
STOOL ROUTINE ANALYSIS			
Color	Brownish	Brown	
Consistency	Semisolid	Solid - Semi solid	
Reaction (pH)	Alkaline	Acidic - Alkaline	
Method : Methyl Red & Bromothymol Blue			
Mucous	Absent	Absent	
Blood	Absent	Absent	
Pus cells	2-3/hpf	Few	/hpf
Epithelial cells	1-2/hpf	--	/hpf
RBC	Absent	Absent	/hpf
Ova	Not found	Absent	/hpf
Cyst	Not found	Absent	/hpf
Starch granules	Absent	None to small amount	/hpf
Vegetable cells	Absent	--	/hpf
Fat globules	Absent	Absent	/hpf
Others	Nil		/hpf
Method : Microscopy (Concentration technique)			

END OF REPORT

DR.UMA SAROJINI .K   MBBS.,DCP.,

Scan to Validate

ARTHI SCANS

Obli Towers, 594, D.B. Road, R. S. Puram, Coimbatore-641 002. Mobile : 99430 99994   email: info@arthiscans.com

Patient Name : MR. GOPALAKRISHNAN R

Age / Gender : 60 years / Male

Patient ID : 70277

Referral : MediWheel

Collection Time : Nov 27, 2021, 08:28 a.m.

Reporting Time : Nov 27, 2021, 03:38 p.m.

Sample ID :

002233121

Test Description	Value(s)	Reference Range

BLOOD GROUP & RH TYPING

Blood Group (ABO typing)

    Method : Manual-Hemagglutination

"A"

RhD Factor (Rh Typing)

    Method : Manual hemagglutination

Positive

END OF REPORT

DR.UMA SAROJINI .K   MBBS.,DCP.,

Scan to Validate

ARTHI SCANS

Obli Towers, 594, D.B. Road, R. S. Puram, Coimbatore-641 002. Mobile : 99430 99994   email: info@arthiscans.com

Patient Name : MR. GOPALAKRISHNAN R

Age / Gender : 60 years / Male

Patient ID : 70277

Referral : MediWheel

Collection Time : Nov 27, 2021, 08:28 a.m.

Reporting Time : Nov 27, 2021, 03:38 p.m.

Sample ID :

002233121

Test Description	Value(s)	Reference Range

Glycosylated HbA1c

HbA1c (GLYCOSYLATED HEMOGLOBIN), BLOOD	5.5	%
Method : (HPLC, NGSP certified)		
Estimated Average Glucose :	111.15 -	mg/dL

Interpretation

As per American Diabetes Association (ADA)	
Reference Group	HbA1c in %
Non diabetic adults >=18 years	<5.7
At risk (Prediabetes)	5.7 - 6.4
Diagnosing Diabetes	>= 6.5
Therapeutic goals for glycemic control	Age > 19 years Goal of therapy: < 7.0 Action suggested: > 8.0 Age < 19 years Goal of therapy: <7.5

Note:

1. Since HbA1c reflects long term fluctuations in the blood glucose concentration, a diabetic patient who is recently under good control may still have a high concentration of HbA1c. Converse is true for a diabetic previously under good control but now poorly controlled .

2. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targeting a goal of < 7.0 % may not be appropriate.

Comments

HbA1c provides an index of average blood glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations.

DR.UMA SAROJINI .K MBBS.,DCP.,

Scan to Validate

Patient Name : MR. GOPALAKRISHNAN R

Age / Gender : 60 years / Male

Patient ID : 70277

Referral : MediWheel

Collection Time : Nov 27, 2021, 08:28 a.m.

Reporting Time : Nov 27, 2021, 03:38 p.m.

Sample ID :

002233121

Test Description	Value(s)	Reference Range

ADA criteria for correlation between HbA1c & Mean plasma glucose levels.

HbA1c(%)	Mean Plasma Glucose (mg/dL)
6	126
7	154
8	183
9	212
10	240
11	269
12	298

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,

Scan to Validate

Obli Towers, 594, D.B. Road, R. S. Puram, Coimbatore-641 002. Mobile : 99430 99994 email: info@arthiscans.com

Patient Name : MR. GOPALAKRISHNAN R

Age / Gender : 60 years / Male

Patient ID : 70277

Referral : MediWheel

Collection Time : Nov 27, 2021, 08:28 a.m.

Reporting Time : Nov 27, 2021, 03:38 p.m.

Sample ID :

002233121

Test Description	Value(s)	Reference Range	

THYROID PROFILE TEST - TOTAL

Test Description	Value(s)	Reference Range	
T3-Total	122.78	60 - 200	ng/dL
T4-Total	10.40	4.52 - 12	ug/dL
TSH-Ultrasensitive	1.24	0.32 - 5.5	uIU/mL

Method : CLIA

Interpretation

TSH	T3	T4	Suggested Interpretation for the Thyroid Function Tests Pattern
Raised	Within range	Within range	Raised Within Range Within Range .Isolated High TSHespecially in the range of 4.7 to 15 m1U/m1 is commonly associated with Physiological & Biological TSH Variability. Subclinical Autoimmune Hypothyroidism.Intermittent 14 therapy for hypothyroidism .Recovery phase after Non-Thyroidal illness"
Raised	Decreased	Decreased	Chronic Autoimmune Thyroiditis Post thyroidectomy,Post radioiodine Hypothyroid phase of transient thyroiditis"
Raised or within range	Raised	Raised or within range	Interfering antibodies to thyroid hormones (anti-TPO antibodies)Intermittent 14 therapy or T4 overdose •Drug interference- Amiodarone, Heparin,Beta blockers,steroids, anti-epileptics.
Decreased	Raised or within range	Raised or within range	Isolated Low TSH -especially in the range of 0.1 to 0.4 often seen in elderly & Range Range associated with Non-Thyroidal illness .Subclinical Hyperthyroidism .Thyroxine ingestion'
Decreased	Decreased	Decreased	Central Hypothyroidism .Non-Thyroidal illness .Recent treatment for Hyperthyroidism (TSH remains suppressed)"
Decreased	Raised	Raised	Primary Hyperthyroidism (Graves' disease).Multinodular goitre, Toxic nodule •Transient thyroiditis:Postpartum, Silent (lymphocytic), Postviral (granulomatous,subacute, DeQuervain's),Gestational thyrotoxicosis with hyperemesis gravidarum"
Decreased Within Rang	Raised	Within range	T3 toxicosis •Non-Thyroidal illness
Within range	Decreased	Within range	Isolated Low T3-often seen in elderly & associated Non-Thyroidal illness In elderly the drop in 13 level can be upto 25%.

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,

Scan to Validate

ARTHI SCANS

Obli Towers, 594, D.B. Road, R. S. Puram, Coimbatore-641 002. Mobile : 99430 99994   email: info@arthiscans.com

Patient Name : MR. GOPALAKRISHNAN R

Age / Gender : 60 years / Male

Patient ID : 70277

Referral : MediWheel

Collection Time : Nov 27, 2021, 08:28 a.m.

**Reporting Time :** Nov 27, 2021, 03:38 p.m.

Sample ID :

002233121

Test Description	Value(s)	Reference Range	
LIPID PROFILE			
Cholesterol-Total	187	Desirable level | < 200	mg/dL
Method : Spectrophotometry		Borderline High | 200-239	
		High | >or = 240	
Triglycerides	77	Normal: < 150	mg/dL
Method : Serum, Enzymatic, endpoint		Borderline High: 150-199	
		High: 200-499	
		Very High: >= 500	
HDL Cholesterol	59	Normal: > 40	mg/dL
Method : Serum, Direct measure-PEG		Major Risk for Heart: < 40	
LDL Cholesterol	112.60	Optimal < 100	mg/dL
Method : Enzymatic selective protection		Near / Above Optimal 100-129	
		Borderline High 130-159	
		High 160-189	
		Very High >or = 190	
VLDL Cholesterol	15.40	6 - 38	mg/dL
Method : Serum, Enzymatic			
CHOL/HDL Ratio	**3.17**	3.5 - 5.0	
Method : Serum, Enzymatic			
LDL/HDL Ratio	**1.91**	2.5 - 3.5	
Method : Serum, Enzymatic			

Note:

8-10 hours fasting sample is required.

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,

Scan to Validate

Patient Name : MR. GOPALAKRISHNAN R

Age / Gender : 60 years / Male

Patient ID : 70277

Referral : MediWheel

Collection Time : Nov 27, 2021, 08:28 a.m.

Reporting Time : Nov 27, 2021, 03:38 p.m.

Sample ID :

002233121

Test Description	Value(s)	Reference Range	
RENAL PROFILE			
Urea	25.0	19-42	mg/dL
Method : Uricase			
Blood Urea Nitrogen-BUN	11.67	9-20	mg/dL
Method : Serum, Urease			
Creatinine	0.9	0.66-1.25	mg/dL
Method : Serum, Jaffe			
Uric Acid	5.4	3.5-8.5	mg/dL
Method : Serum, Uricase			

Remark:

In blood, Urea is usually reported as BUN and expressed in mg/dl. BUN mass units can be converted to urea mass units by multiplying by 2.14.

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,

Scan to Validate

Patient Name : MR. GOPALAKRISHNAN R

Age / Gender : 60 years / Male

Patient ID : 70277

Referral : MediWheel

Collection Time : Nov 27, 2021, 08:28 a.m.

Reporting Time : Nov 27, 2021, 03:38 p.m.

Sample ID :

002233121

Test Description	Value(s)	Reference Range	
LIVER FUNCTION TEST			
Total Protein	7.8	6.3-8.2	g/dL
Method : Serum, Biuret, reagent blank end point			
Albumin	4.1	3.5-5.0	g/dL
Method : Serum, Bromocresol green			
Globulin	**3.70**	1.8 - 3.6	g/dL
Method : Serum, EIA			
A/G Ratio	**1.11**	1.2 - 2.2	
Method : Serum, EIA			
Bilirubin - Total	0.4	0.3-1.2	mg/dL
Method : Serum, Jendrassik Grof			
Bilirubin - Direct	0.1	< 0.2	mg/dL
Method : Serum, Diazotization			
Bilirubin - Indirect	0.3	0.1 - 1.0	mg/dL
Method : Serum, Calculated			
SGOT	24	17-59	U/L
Method : Serum, UV with P5P, IFCC 37 degree			
SGPT	27	21-72	U/L
Method : Serum, UV with P5P, IFCC 37 degree			
Alkaline Phosphatase	67	30 - 120	U/L
Method : PNPP-AMP Buffer/Kinetic			
GGT-Gamma Glutamyl Transpeptidae	24	< 55	U/L
Method : Serum, G-glutamyl-carboxy-nitoanilide			

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,

Scan to Validate

ARTHI SCANS

Obli Towers, 594, D.B. Road, R. S. Puram, Coimbatore-641 002. Mobile : 99430 99994 email: info@arthiscans.com

Patient Name : MR. GOPALAKRISHNAN R

Age / Gender : 60 years / Male

Patient ID : 70277

Referral : MediWheel

Collection Time : Nov 27, 2021, 08:28 a.m.

Reporting Time : Nov 27, 2021, 03:38 p.m.

Sample ID :

002233121

Test Description	Value(s)	Reference Range	

PSA-Total (Prostate-specific antigen-Total)

PSA Profile *

PSA (Prostate Specific Antigen)-Total	1.20	0 - 4.0	ng/mL
Method : Serum, CLIA			

Interpretation:

1. Increased levels are noted in Prostate cancer, Bengin prostatic hypertrophy, Prostatitis

PSA (Prostate-Specificantigen)-Free *	-	0.0 - 0.5	ng/mL
Method : Serum, CLIA			

Interpretation & Remarks:

- Normal results do not eliminate the possibility of prostate cancer.

- Values obtained with different assay methods or kits may be different and cannot be used interchangeably.

- Tumor markers are not specific for malignancy. Test results cannot be interpreted as absolute evidence for the presence or absence of malignant disease

- Specimens drawn from patients undergoing prostate manipulation, especially needle biopsy and transurethral resection, may show erroneously high prostatic-specific antigen (PSA) results. Care should be taken that specimens are drawn before these procedures are performed.

- The percentage of free PSA can be used to estimate how likely it is that a biopsy will show cancer.

- If the percentage of free PSA is higher than 25%, the likelihood of prostate cancer is about 8%.

- If the percentage of free PSA is less than 10%, then the likelihood of prostate cancer rises to 56%.

Free PSA / Total PSA %	-	-	
Method : Serum			

Interpretation

- When total prostate-specific antigen (PSA) concentration is <2.0 ng/mL, the probability of prostate cancer in asymptomatic men is low, further testing and free PSA may provide little additional information. When total PSA concentration is >10.0 ng/mL, the probability of cancer is high and prostate biopsy is generally recommended.

- The total PSA range of 4.0 to 10.0 ng/mL has been described as a diagnostic "gray zone," in which the free:total PSA ratio helps to determine the relative risk of prostate cancer (see table below). Therefore, some urologists recommend using the free:total ratio to help select which men should undergo biopsy. However even a negative result of prostate biopsy does not

DR.UMA SAROJINI .K MBBS.,DCP.,

Scan to Validate

Patient Name : MR. GOPALAKRISHNAN R

Age / Gender : 60 years / Male

Patient ID : 70277

Referral : MediWheel

Collection Time : Nov 27, 2021, 08:28 a.m.

Reporting Time : Nov 27, 2021, 03:38 p.m.

Sample ID :

002233121

Test Description	Value(s)	Reference Range

rule-out prostate cancer. Up to 20% of men with negative biopsy results have subsequently been found to have cancer.

Based on free:total PSA ratio: the percent probability of finding prostate cancer on a needle biopsy by age in years:

| Free:total PSA ratio	50-59 years	60-69 years	> or =70 years
< or =0.10	49.2%	57.5%	64.5%
0.11-0.18	26.9%	33.9%	40.8%
0.19-0.25	18.3%	23.9%	29.7%
>0.25	9.1%	12.2%	15.8%

Cautions

- Normal results do not eliminate the possibility of prostate cancer.
- Values obtained with different assay methods or kits may be different and cannot be used interchangeably
- Tumor markers are not specific for malignancy. Test results cannot be interpreted as absolute evidence for the presence or absence of malignant disease.

Interfering factors :

- Prostatic massage
- Proctoscopy
- Prostatic biopsy
- Prostate cancer patients receiving treatment with antiandrogens and luteinizing hormone-releasing factor agonists may exhibit markedly decreased levels of PSA. Also, men treated for benign prostatic hyperplasia with inhibitors of 5-alpha-reductase (finasteride) may demonstrate a significant reduction in PSA levels compared to values before treatment. Care should be taken in interpreting values for these individuals.
- In patients receiving therapy with high biotin doses (ie, >5 mg/day), no sample should be taken until at least 8 hours after the last biotin administration.

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,

Scan to Validate

Patient Name : MR. GOPALAKRISHNAN R

Age / Gender : 60 years / Male

Patient ID : 70277

Referral : MediWheel

Collection Time : Nov 27, 2021, 08:28 a.m.

**Reporting Time :** Nov 27, 2021, 03:38 p.m.

Sample ID :

002233121

Test Description	Value(s)	Reference Range	
GLUCOSE (F)			
Glucose fasting	88	Normal: 70 - 120	mg/dL
Method : GOD-POD			

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,

Scan to Validate

ARTHI SCANS

Patient Name : MR. GOPALAKRISHNAN R

Age / Gender : 60 years / Male

Patient ID : 70277

Referral : MediWheel

Collection Time : Nov 27, 2021, 08:28 a.m.

**Reporting Time :** Nov 27, 2021, 03:38 p.m.

Sample ID :

002233121

Test Description	Value(s)	Reference Range	
GLUCOSE (PP)			
Blood Glucose-Post Prandial	97	80 - 140	mg/dL
Method : GOD-POD			

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,

Scan to Validate